Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 187004 DDI with CYP and P-gp substrates
NCT02254148Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BI 187004 in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point and Maximum measured concentration of the analyte in plasma. Started Oct 2014; status: completed.
02
Drugs
BI 187004
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT02254148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254148.